Infections following facial composite tissue allotransplantation - Single center experience and review of the literature

American Journal of Transplantation

Volumn 13, Issue 3, 2013, Pages 770-779

  Knoll, B M ^a   Hammond, S P ^a   Koo, S ^a   Issa, N C ^a   Tullius, S G ^a   Baden, L R ^a   Pomahac, B ^a   Marty, F M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Facial composite tissue allotransplantation; infection

Indexed keywords

CEFAZOLIN; COTRIMOXAZOLE; MICAFUNGIN; VALGANCICLOVIR; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; AUTOTRANSPLANTATION; CATHETER INFECTION; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DERMATOPHYTOSIS; FACIAL COMPOSITE TISSUE ALLOTRANSPLANTATION; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; PAROTITIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REVIEW; VIRUS CULTURE;

ADULT; ANTI-INFECTIVE AGENTS; CATHETER-RELATED INFECTIONS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FACE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; MALE; MIDDLE AGED; PNEUMONIA; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; SURGICAL WOUND INFECTION; TISSUE TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84874407318     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12013     Document Type: Review

References (17)

1. Devauchelle B, Badet L, Lengelé B, et al. First human face allograft: Early report. Lancet 2006; 368: 203-209.
2. Dubernard J-M, Lengelé B, Morelon E, et al. Outcomes 18 months after the first human partial face transplantation. N Engl J Med 2007; 357: 2451-2460.
3. Guo S, Han Y, Zhang X, et al. Human facial allotransplantation: A 2-year follow-up study. Lancet 2008; 372: 631-638.
4. Siemionow M, Papay F, Alam D, et al. Near-total human face transplantation for a severely disfigured patient in the USA. Lancet 2009; 374: 203-209.
5. Lantieri L, Meningaud JP, Grimbert P, et al. Repair of the lower and middle parts of the face by composite tissue allotransplantation in a patient with massive plexiform neurofibroma: A 1-year follow-up study. Lancet 2008; 372: 639-645.
6. Lantieri L, Hivelin M, Audard V, et al. Feasibility, reproducibility, risks and benefits of face transplantation: A prospective study of outcomes. Am J Transplant 2011; 11: 367-378.
7. Barret JP, Gavaldà J, Bueno J, et al. Full face transplant: The first case report. Ann Surg 2011; 254: 252-256.
8. Sicilia-Castro D, Gomez-Cia T, Infante-Cossio P, et al. Reconstruction of a severe facial defect by allotransplantation in neurofibromatosis type 1: A case report. Transplant Proc 2011; 43: 2831-2837.
9. BenMarzouk-Hidalgo OJ, Cordero E, Gõmez-Cía T, et al. First face composite-tissue transplant recipient successfully treated for cytomegalovirus infection with preemptive valganciclovir treatment. Antimicrob Agents Chemother 2011; 55: 5949-5951.
10. Pomahac B, Pribaz J, Eriksson E, et al. Restoration of facial form and function after severe disfigurement from burn injury by a composite facial allograft. Am J Transplant 2011; 11: 386-393.
11. Pomahac B, Pribaz J, Eriksson E, et al. Three patients with full facial transplantation. N Engl J Med 2012; 366: 715-722.
12. Richter ER, Dias JK, Gilbert JE 2nd, Atherton SS,. Distribution of herpes simplex virus type 1 and varicella zoster virus in ganglia of the human head and neck. J Infect Dis 2009; 200: 1901-1906.
13. Saavedra AP, Bueno EM, Granter SR, Pomahac B,. Transmission of donor-specific skin condition from donor to recipient of facial allograft. Am J Transplant 2011; 11: 1340.
14. Gordon CR, Avery RK, Abouhassan W, Siemionow M,. Cytomegalovirus and other infectious issues related to face transplantation: Specific considerations, lessons learned, and future recommendations. Plast Reconstr Surg 2011; 127: 1515-1523.
15. Painter W, Robertson A, Trost LC, Godkin S, Lampert B, Painter G,. First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses. Antimicrob Agents Chemother 2012; 56: 2726-2734.
16. Griffiths PD, Stanton A, McCarrell E, et al. Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: A phase 2 randomised placebo-controlled trial. Lancet 2011; 377: 1256-1263.
17. Kharfan-Dabaja MA, Boeckh M, Wilck MB, et al. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Infect Dis 2012; 12: 290-299.